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The kinase Fyn, the microtubule-associated protein tau and the peptide amyloid-β (Aβ)
constitute a toxic triad in Alzheimer’s disease (AD). Tau’s subcellular localization is mainly
regulated by phosphorylation whereas Fyn’s localization is dictated by palmitoylation
targeting it to the plasma membrane in a reversible manner. We have previously shown
that tau is required for Fyn to be targeted to the dendritic spine. We had also shown that
a truncated form of tau (tau) that accumulates in the cell soma is capable of trapping
Fyn and preventing it from entering the spine. Here we determined that palmitoylation is
required for Fyn’s membrane and spine localization. We further evaluated the functional
consequences of neuronal over-expression of the constitutively active Y531F mutant form
of Fyn (FynCA) in transgenic mice. We found that the FynCA transgenic mice displayed a
reduced weight, a massively reduced lifespan and a high level of hyperactivity. The lifespan
of the FynCA mice was only slightly extended by crossing them with tau transgenic
mice, possibly reflecting differences in expression patterns of the transgenes and high
levels of transgenic FynCA compared to endogenous Fyn. Analysis of synaptosomes
revealed that FynCA accumulated at high levels in the spine, resulting in increased
levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472. Tau was
strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and
immunohistochemistry indicating that an increased tyrosine kinase activity of Fyn has
down-stream consequences for serine/threonine-directed phosphorylation.
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INTRODUCTION
In Alzheimer’s disease (AD), serine/threonine-directed phospho-
rylation has attracted significantly more attention than tyrosine-
directed phosphorylation (Götz et al., 2013). One of the rea-
sons is that the microtubule-associated protein tau, a protein
implicated in AD, contains 80 serines and threonines, many
of which have been shown to be phosphorylated under dis-
ease conditions, compared to only 5 tyrosine residues (Chen
et al., 2004). When tau transgenic mice as a model of AD are
analyzed this routinely includes the assessment of the phos-
phorylation status of relevant serine and threonine residues,
but rarely that of tyrosines. Similarly, to establish the sequence
of tau-related cytoskeletal changes in AD, the serine/threonine-
directed antibody AT8 and not a tyrosine-directed antibody
has been used (Braak et al., 1994). However, it is increas-
ingly appreciated that tyrosine phosphorylation has also an
important role in AD (Boehm, 2013). Of tau’s five tyrosine
residues, Y18 is particularly interesting because it is specif-
ically phosphorylated by the tyrosine-directed kinase Fyn, a
member of the Src family of non-receptor tyrosine kinases
(http://cnr.iop.kcl.ac.uk/hangerlab/tautable) (Figure 1A).
Under physiological conditions, the majority of tau is local-
ized to the axon, whereas tau’s “counterpart,” MAP2, is mainly
localized to the dendrite. However, as we have found recently,
tau is also localized, albeit at lower levels, to the dendrite where
it serves an important function that cannot be taken over by
MAP2 (Ittner et al., 2010): Tau is required to target Fyn to
the dendritic spine where it phosphorylates the NMDA recep-
tor, a prerequisite for recruiting the postsynaptic density (PSD)
(95 kD) protein (PSD-95) into a protein complex. This complex
then mediates the excitotoxic signaling triggered by Aβ, a pep-
tide that aggregates and forms amyloid plaques in AD brains.
In the absence of tau or when a form of tau is expressed that
accumulates in the cell soma and is excluded from the den-
drite (tau, Figure 1B), Fyn is prevented from entering the
spine and thereby, Aβ cannot excitotoxically signal through the
NMDA receptor (either directly, or indirectly) any more (Ittner
et al., 2010). When a full-length form of tau is expressed that
carries the pathogenic P301L mutation found in frontotempo-
ral dementia, excitotoxic signaling is augmented because of an
increased dendritic localization of phosphorylated mutant tau
and consequently, increased levels of dendritic Fyn (Ittner and
Götz, 2011). These data are supported by the finding that Aβ
causes missorting of endogenous tau into the dendritic com-
partment (Zempel et al., 2010). Not surprisingly, overexpres-
sion of wild-type murine Fyn induces synaptic and cognitive
impairments in a transgenic mouse model with Aβ accumula-
tion (Chin et al., 2005), and deletion of Fyn ameliorates some
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FIGURE 1 | Structure of Fyn, its membrane localization, and constructs
used for expression of Fyn, tau and Tau. (A) Fyn is a 59 kDa protein that
contains an amino-terminal Src-homology (SH) region with acylation sites, a
unique domain, an SH3 domain (with which it interacts with PXXP motifs), an
SH2 domain (with which it interacts with phospho-tyrosine), an SH1/kinase
domain, and a carboxy-terminal regulatory tail. The most amino-terminal
glycine residue can be myristoylated, which occurs co-translationally on free
ribosomes. In addition, Fyn’s amino-terminal cysteines C3 and C6 can be
palmitoylated, and it is this acylation reaction that anchors the kinase to the
plasma membrane. (B) Expression constructs for human Fyn were either
wild-type, C3S/C6S to prevent palmitoylation, or Y531F to generate a
constitutively active form of Fyn (FynCA). Tau was expressed either as
full-length [with the longest human tau isoform, hTau40, containing four
microtubule-binding domains (MBDs) indicated in black] or a truncated form
(tau) lacking the MBDs. For detection of tau and Fyn, myc, GFP and V5
were used as tags as indicated.
of the phenotypes induced by Aβ (Chin et al., 2004). Together,
this established the notion of a toxic triad of the three molecules,
tau, Fyn and Aβ (Haass and Mandelkow, 2010), presenting Aβ
as the trigger, and tau as the bullet in AD pathogenesis (Bloom,
2014).
Fyn is a 59 kDa protein that exists as two isoforms due to alter-
native splicing of exon 7, with FynT being expressed in T-cells,
and FynB in the brain and additional organs (Kramer-Albers and
White, 2011). Fyn contains, in this order, an amino-terminal Src-
homology (SH) region with acylation sites, a unique domain,
an SH3 domain (with which it interacts with PXXP motifs), an
SH2 domain (with which it interacts with phospho-tyrosine),
an SH1/kinase domain, and a carboxy-terminal regulatory tail
(Figure 1A). The most amino-terminal glycine residue can be
myristoylated, which occurs co-translationally on free ribosomes.
In addition, Fyn’s amino-terminal cysteines, C3 and C6, can
be palmitoylated, and it is this acylation reaction that anchors
the kinase to the plasma membrane. Palmitoylation in general
enhances the hydrophobicity of proteins and contributes to their
membrane association. In contrast to myristoylation, palmitoy-
lation is usually reversible (because the bond between palmitic
acid and protein is often a thioester bond) (Figure 1A). A good
example of another palmitoylated protein in the dendritic spine
is PSD-95. Interestingly, palmitoylation of Fyn seems to direct the
SH4 domain away from the membrane, which may be impor-
tant for the interaction of Fyn with target proteins (Rawat and
Nagaraj, 2010).
The activity of Fyn is regulated by differential phosphoryla-
tion at multiple sites (Kramer-Albers and White, 2011). In its
inactive state, the regulatory tyrosine at the carboxy-terminus
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(Y531 in mouse FynB) is phosphorylated, forming an intra-
molecular bond with the SH2 domain of the kinase. This
phosphorylation negatively regulates kinase activity (Nada et al.,
1993). Furthermore, the SH3 domain binds intra-molecularly to
a linker region located between the SH2 and the kinase domain.
This keeps the kinase in an inactive closed conformation in which
both protein binding domains are occupied. Upon dephospho-
rylation of the carboxy-terminal regulatory tyrosine residue by
tyrosine phosphatases, the intramolecular binding to the SH2
domain is abolished. Loss of SH2-dependent folding alters the
conformation of the kinase to generate a more open form mak-
ing the SH2 and SH3 domains available for downstream protein
interactions. Furthermore, the open conformation enables an
intermolecular auto-phosphorylation of Y420 that stabilizes the
active state of the catalytic site (Roskoski, 2004). Src kinases
can also be stimulated by interfering with the inhibitory intra-
molecular binding of SH2 and SH3 domains which both can
bind to external ligands leading to an activation of the kinase
(Ostareck-Lederer et al., 2002; Sette et al., 2002).
Tau interacts with Fyn at least in two ways. Firstly, Y18 is phos-
phorylated by Fyn, and the phosphorylated motif interacts with
Fyn via Fyn’s SH2 domain (Usardi et al., 2011). Secondly, Tau
contains seven PXXP motifs located in the amino-terminus (all
of which are retained in the tau construct). Of these, the sev-
enth proline-rich RTPPKSP motif has been shown to be crucial
for the interaction with the SH3 domain of Fyn and other Src
non-receptor tyrosine kinases (Lee et al., 1998; Bhaskar et al.,
2010; Ittner et al., 2010). Interestingly, this motif is also criti-
cal in the interaction of tau with the heterotrimeric phosphatase
PP2A (Sontag et al., 2012). The PP2A regulatory subunit Bα binds
to and dephosphorylates tau, and thereby regulates microtubule
stability (Kins et al., 2001; Sontag et al., 2012). When Fyn is
bound to the (seventh) proline-rich RTPPKSP motif that is con-
served in both tau and MAP2, this inhibits the interaction of
PP2A/Bα with either tau or MAP2. The corresponding synthetic
RTPPKSP peptide, but not the phosphorylated RpTPPKSP ver-
sion, competes with tau and MAP2 for binding to PP2A/Bα. This
finding is remarkable because the down-regulation of PP2A/Bα
and the deregulation of Fyn/tau interactions have been linked to
enhanced tau phosphorylation in AD (Sontag et al., 2012). Why
in tau knock-out mice, MAP2 that is mainly a dendritic protein
cannot compensate for the absence of tau and target Fyn to the
dendritic spine is not understood, especially as both MAP2 and
tau can efficiently bind Fyn (Sontag et al., 2012; Lashuel et al.,
2013). Not only tau but also MAP2 have been shown to bind to
Fyn via Fyn’s SH3 domain (Zamora-Leon et al., 2001).
Here, we aimed to address how Fyn is localized subcellu-
larly in vitro and what the functional consequences are of the




The C3S/C6S double mutation was introduced by PCR into the
lentiviral vector Fyn-myc pLUV6 that contains the human Fyn
isoform 1 cDNA fused to a myc tag (Ittner et al., 2010). The
resultant mutant construct was subcloned into the pGEM-T easy
vector by TA ligation (Promega), followed by ApaI/SalI digestion
and ligation into the pEGFP-N1 vector (Clontech) to generate a
C3S/C6S Fyn-EGFP construct. Similarly, the Y531F mutation was
cloned by PCR, with or without a myc-tag, and subcloned via a
unique XhoI site into the murine Thy1.2 expression vector pEX12
for subsequent neuronal expression in transgenicmice (Ittner and
Götz, 2007). The plasmids were sequenced using the service of
the AEGRC sequencing facility (University of Queensland). The
resulting transgenic mice were labeled FynCA.
CELL CULTURE
HEK293T cells were cultured in DMEM medium, supplemented
with 2mM Glutamax (Life Technologies) and 10% FBS (Sigma).
Cells were seeded as 50% confluency in 6 cm culture dishes
and allowed to grow for 24 h before transfection. For high effi-
ciency transfection, lipofectamine LTX (Invitrogen) was used
in a 2:1 ratio to DNA. Hippocampal neurons from E18 wild-
type or Tau knock-out (Tucker et al., 2001) mouse pups were
plated onto poly-D-lysine coated coverslips in a 12-well plate at
a density of 5000 cells/well. As a plating medium, Neurobasal
medium was used, supplemented with 5% FBS (Hyclone),
2% B27 (Life Technologies), 2mM Glutamax, and 50 U/mL
penicillin/streptomycin. Neurons were switched to serum-free
Neurobasal medium 24 h post-seeding and half the medium was
changed twice a week. Neurons were transfected at DIV 18 using
lipofectamine 2000 (Invitrogen).
GENERATION OF TRANSGENIC MICE
FynCA transgenic mice were generated by pronuclear microin-
jection as described previously (Ittner and Götz, 2007). tau74
mice have been generated previously, by removing amino acids
256–441 from the longest human tau isoform, htau40, and
expressing this truncated form of tau under control of the
murine Thy1.2 promoter (Ittner et al., 2010). As a tau knock-
out strain, mice were used that have a GFP cassette inserted
in frame into the first coding exon, resulting in a fusion pro-
tein that contains the first 31 amino acids of tau (Tucker et al.,
2001). Animal experimentation has been approved by the Animal
Experimentation Committee of the University of Queensland
(QBI/327/11/NHMRC/ARC/BREED, QBI/027/12/ NHMRC).
IMMUNOHISTOCHEMISTRY
Mice were immersion fixed in 4% PFA rather than perfused
because of their small size, brains embedded in paraffin and
7μm sections obtained as described (Deters et al., 2008). For
antigen retrieval, the sections were microwaved in AR buffer
(Dako Envision Flex Target Retrieval Solution low pH #K8005)
for 15min on low power before the buffer started to boil. The
sections were then left to cool for 1 h in the AR buffer at RT.
Blocking was done in 20% FBS, 1% BSA in TBST for 1 h at RT.
Primary antibodies were used over night at 4◦C and secondary
antibodies for 1.5 h at RT. Primary antibodies were Myc-Tag rab-
bit mAb (Cell Signaling Technologies, #71D10, used at 1:100)
and anti-Human PHF-Tau Monoclonal Antibody AT8 (Thermo
Fisher, MN1020, used at 1:400). Secondary antibodies were poly-
clonal goat anti-rabbit IgG biotinylated (Dako, #E0432, used at
1:500) and polyclonal rabbit anti-mouse IgG biotinylated (Dako,
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#E0413, used at 1:500). The VectaStain Elite ABC Kit #PK6102
was used and Envision Flex DAB chromogen (Dako, #DM827)
and Envision Flex Substrate Buffer (Dako, # DM823) for DAB
development. Haematoxylin was used for counter-staining.
SYNAPTOSOMAL EXTRACTION ANDWESTERN BLOT ANALYSIS
Synaptosomes from the mouse forebrain (n = 4 for the three
genotypes) were prepared using a modified volume-adjusted pro-
tocol based on a protocol described previously (Ittner et al.,
2010). In brief, the tissue was homogenized in sucrose buffer
(1ml/60mg tissue. 0.32M sucrose, 1mM NaHCO3, 1mM
MgCl2, 0.5mM CaCl2) using a tissue homogenizer. Brain
homogenate was centrifuged at 1400 g for 10min and cleared
by centrifugation at 720 g for 10min. 200μL of supernatant
was collected as whole brain lysate and the pellet containing
cell debris and nuclei was discarded. The remaining super-
natants were then centrifuged at 13,800 g for 10min to obtain
the crude synaptosomes in the pellet (P). The pellet was resus-
pended in 200μl Sucrose Buffer, layered over 1.8mL pre-cooled
5% Ficoll and centrifuged at 45,000 g for 45min. The super-
natant was then removed carefully and the pellet resuspended in
200μL pre-cooled 5% Ficoll, which was then layered over 1.8mL
pre-cooled 13% Ficoll and centrifuged at 45,000 g for 45min.
A milky interface containing the synaptosomes was recovered,
topped-up with 5% Ficoll to 2mL and centrifuged at 45,000 g
for 25min to pellet the synaptosomes. Purified synaptosomes
were further extracted sequentially with buffers of increasing
stringency: pH6 (40mM Tris-HCl, 2% Triton X-100, 0.5mM
CaCl2); pH8 (20mM Tris-HCl, 1% Triton X-100); and SDS (5%
SDS). The SDS buffer extract contains strongly PSD-associated
proteins. This fraction was named “PSD.” All centrifugations
were carried out at 4◦C. For Western blot analysis, the follow-
ing primary antibodies were used: total Tau (Dako, polyclonal,
1:5,000), Fyn (Fyn15; monoclonal, Santa Cruz, 1:500), PSD-95
(Millipore, 1:2,000), GAPDH (polyclonal, Millipore, 1:5,000),
NR2b (polyclonal, Millipore, 1:1,000), pTyr1472- NR2b (poly-
clonal, Sigma, 1:1,000), Myc-tag (71D10, rabbit monoclonal,
1:2,000), AT8 (phospho-tau, pSer202 + pThr205, monoclonal,
Thermo, 1:1,000), 12E8 (phospho-tau pSer262 (+ pS356)),
polyclonal, Thermo, 1:4,000), HT7 (human Tau, monoclonal,
Thermo, 1:2,000), and Actin (monoclonal, Millipore, clone C4,
monoclonal, 1:5,000).
RESULTS
PALMITOYLATION OF Fyn IS REQUIRED FOR SPINE LOCALIZATION
Fyn contains two cysteines (C3 and C6) that are acetylated in a
palmitoylation reaction. To determine the role of these residues
in subcellular localization we mutated the palmitoylation signal
by replacing the two cysteines by serines as described (Wolven
et al., 1997), and equipped Fyn with a GFP tag. When transfected
into HEK293 cells, this revealed a membrane association for wild-
type Fyn (Figure 2A). Fyn(C3S/C6S), in contrast, was excluded
from the plasma membrane and accumulated intracellularly in
endosomes (Sandilands et al., 2007) (Figure 2B). We next deter-
mined the subcellular localization in primary hippocampal cul-
tures obtained from wild-type mouse embryos. After 21 days
(DIV2) in culture, the neurons displayed a myriad of spines.
We co-transfected the cultures with RFP and either Fyn-GFP
or Fyn(C3S/C6S)-GFP and found that wild-type Fyn was local-
ized to spines (Figures 2C–E) whereas Fyn(C3S/C6S)-GFP was
excluded from entering the spines (Figures 2F–H). Together this
reveals that palmitoylation and hence, membrane association, is
required for the localization of Fyn into dendritic spines.
We have previously shown that tau in tau74 transgenic
mice is localized to the cell body, but excluded from the dendritic
compartment (Ittner et al., 2010). This finding was also supported
biochemically, by analyzing synaptosomal preparations and com-
paringtau localization with that of full-length tau. To determine
whether tau is also excluded from the dendritic compartment
and in particular, spines, in primary neuronal cultures, we trans-
fected both full-length tau equipped with a V5 tag (Tau-V5)
together with RFP, and tau-V5 together with RFP, respectively,
using primary neuronal cultures derived from tau knock-out
mice. This showed that full-length tau is distributed through-
out the neuron, but excluded from the spines (Figures 3A–C).
In contrast, tau was dramatically reduced from the dendritic
compartment and levels were found to be below detection lev-
els past the secondary branch-point (as indicated by the arrows)
(Figures 3D–F). We next determined whether expression oftau
would affect Fyn localization, by co-transfecting wild-type neu-
rons with Fyn-EGFP, RFP, and tau-V5 (Figures 3G–K). We
found that different from tau74 mice in which transgenic over-
expression of tau (or knocking-out endogenous tau) prevented
endogenous Fyn from entering the spines (Ittner et al., 2010),
transfecting tau into primary neurons was not capable of pre-
venting transfected Fyn (Fyn-EGFP) from entering the spine,
possibly reflecting differences in expression levels.
MICE WITH A CONSTITUTIVE EXPRESSION OF Fyn ARE
CHARACTERIZED BY REDUCED WEIGHT, HYPERACTIVITY, AND
PREMATURE DEATH
In brain, Fyn is expressed in both neurons and glial cells, and in
both cell-types, tau has an important function in regulating Fyn
(Klein et al., 2002; Ittner et al., 2010). To establish a mouse model
with constitutive expression of Fyn in neurons, we introduced
the Y531F mutation into the human Fyn cDNA and cloned this
“FynCA” cDNA into the mThy1.2 expression vector for neuronal
expression, generating constructs that either contained or did not
contain the myc tag for subsequent detection (Figure 1A). We
generated a series of transgenic founders by pronuclear injection
of C57BL/6 × DBA/2 oocytes: four (#11, 15, 16, and 17) with-
out a myc tag, and 10 (#4, 12, 13, 14, 20, 22, 24, 35, 55, and 58)
with a tag. We screened the offspring obtained from these FynCA
founder animals byWestern blotting and found that whenever the
transgene-positive offspring died early (what happened around 3
weeks of age), the transgene was expressed at detectable levels,
whereas when the mice did not die at an early age the offspring of
that particular founder did not express the transgene at detectable
levels (Figure 4A). We specifically identified founders #14, 35,
and 55 as generating offspring characterized by early lethality.
The transgene-positive offspring derived from these lines was sig-
nificantly smaller, as shown for #55 offspring (Figure 4B), and
showed less weight gain than the non-transgenic littermates such
that by 2–3 weeks of age they would only have half the weight of
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FIGURE 2 | Palmitoylation and hence, membrane association, is required
for the localization of Fyn into dendritic spines. Transfection of Fyn
expression constructs in HEK293 cells (A,B) and primary hippocampal cultures
(C–H) reveals that wild-type Fyn associates with the plasma membrane in
HEK293 cells (A), whereas mutating Fyn’s two cysteines (C3/C6) that are
acetylated in a palmitoylation reaction to cysteines causes Fyn’s accumulation
intracellularly in endosomes (B). In the neuronal cultures, wild-type Fyn is
localized to spines (C–E)whereas Fyn(C3S/C6S)-GFP is excluded from entering
the spines (F–H). RFP (D,G)was used to visualize all neuronal structures
including the spines. Scale bar: 10μm (A,B); 20μm (C–H).
non-transgenic littermates (Figure 4C). The transgenic mice dis-
played persistent tremor and lack of coordination while moving,
as well as pronounced hyperactivity and an altered locomotion
behavior (Supplementary movie, shown at 18 days of age). More
specifically, when separated from the litter they would start run-
ning in circles in the cage for hours, and this could only be halted
when the transgenic mice were put back to the litter. Interestingly,
only a slight separation from the litter was sufficient to re-instigate
this type of behavior, suggesting high levels of anxiety in FynCA
mice. To complement the movie, we recorded the path of four
mice each aged 18 days of age for 1min, after the mice had been
kept isolated in a box for 1 h (Figure 4D).
PARTIAL RESCUE OF FynCA MICE BY CROSSING ONTO Atau
BACKGROUND
We next analyzed the offspring of the FynCA founder animals
both by immuno-histochemistry (Figure 5) andWestern blotting
(Figure 6) using a monoclonal anti-Fyn antibody. The latter
revealed a strong expression of Fyn (59 kDa) in mouse brains
derived from the FynCA founders #14, 35, and 55. As shown for
offspring of founder #55, levels of Fyn in FynCA transgenic mice
were approximately six-fold higher than those for endogenous
murine Fyn in wild-type mice (Figure 6A). The affinity of
the antibody for human and murine Fyn is expected not to
differ because of a 100% homology of the epitope used for
immunization as well as flanking sequences. We next determined
the expression pattern of FynCA in #55 offspring by immuno-
histochemistry using a rabbit anti-myc antibody to visualize
FynCA expression. We found that FynCA was widely expressed
in FynCA transgenic brain (Figure 5A), using non-transgenic
littermates as controls (Figure 5B). Prominent expression of
the FynCA transgene was found in neurites and fiber tracts as
shown for the hippocampus and the fimbria fornix, but the
FynCA transgenic protein was also found accumulating in the
cell bodies e.g., of large motor neurons in the brain stem and in
nuclei such as the pontine nucleus. As tau is a substrate of Fyn
we aimed to assess its phosphorylation in the FynCA mice. The
phospho-Y18-tau-specific antibody 9G3 could not be employed
because it is human tau-specific and does not detect murine
tau phosphorylated at Y18 (Bhaskar et al., 2010). We therefore
aimed to determine whether Ser/Thr-directed phosphorylation
is increased in the presence of constitutively active Fyn. In
human tau transgenic mice phosphorylation of Ser/Thr-epitopes
of tau only occurs as the mice become older. We nonetheless
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FIGURE 3 | Subcellular localization of Fyn and tau. Transfection of tau
knock-out primary neuronal cultures with a full-length tau construct equipped
with a V5 tag (Tau-V5) (A) together with RFP (B) shows distribution of
full-length tau throughout the neuron, but spines are excluded. (Merged
image: C). Transfection of tau-V5 (D) together with RFP (E) reveals that
tau is dramatically reduced from the dendritic compartment, and that levels
are below detection past the secondary branch-point (as indicated by the
arrows) (Merged image: F). When Fyn-EGFP (G) was over-expressed
together with tau-V5 (H) and RFP (I) in wild-type primary neurons, different
from tau74 mice in which transgenic over-expression of tau prevents
endogenous Fyn from entering the spines, transfecting tau into primary
neurons does not prevent transfected Fyn from entering the spine, possibly
reflecting differences in expression levels (Merged image: K). Scale bar:
100μm (A–K).
analyzed 2 week-old FynCA mice using the phosphotau-specific
antibody AT8 (Figure 5C), using non-transgenic littermates as
controls (Figure 5D). We found that the mice were strongly
phosphorylated at the AT8 epitope in fiber tracts as shown for
the hippocampus, and pronounced AT8-immunoreactivity was
also seen in cell bodies in several brain areas.
To determine whether expression of tau would ameliorate
the FynCA pathology at least to a degree that would allow us
to establish FynCA lines from the founder animals, we bred the
FynCA founders with tau74 mice. tau is widely expressed
in the brains of tau74-transgenic mice as revealed with the
human tau-specific antibody HT7, whereas no expression is
found in non-transgenic littermate controls (Ittner et al., 2010).
Based on the co-transfection experiments in primary neurons
(Figures 3G–K) and because of differences in expression patterns
between tau in tau74 mice and FynCA in FynCA55 mice
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FIGURE 4 | FynCA mice are characterized by early mortality, reduced
weight, and hyperactivity. Transgene-positive offspring derived from
FynCA founders #14, 35, and 55 is characterized by early lethality (A).
Crossing FynCA mice with tau mice results in a slight extension of the
lifespan of the FynCA mice. The transgene-positive offspring derived from
these lines tends to be smaller as shown for #55 offspring (B), and to show
less weight gain than the non-transgenic littermates such that by 2–3
weeks of age they weigh only half of their non-transgenic littermates
(Student’s t-test, P < 0.0001) (C). Tracking of four FynCA transgenic mice
(top) and four non-transgenic littermates (bottom) at 18 days of age. The
FynCA mice run in circles and keep this hyperactivity up for hours unless
being put back to their litter (D).
(which is in part due to different integration sites of the trans-
genes) (Figure 5), we expected only a subtle effect on survival.
This is in fact what we observed because the rescue conferred
by tau on the mortality of the FynCA mice was very subtle
(Figure 4A).
FIGURE 5 | Fyn expression in FynCA mice and tau phosphorylation. A
myc-specific antibody was used to reveal Fyn expression in
FynCA-transgenic mice (A), using non-transgenic littermates as controls
(B). Phosphorylation of endogenous tau was revealed using the
Ser202/Thr205-specific antibody AT8, analyzing FynCA-transgenic mice (C)
and non-transgenic littermate controls (D).
INCREASED PHOSPHORYLATION OF NR2b AND tau IN FynCA MICE
We next obtained synaptosomal fractions adopting a previously
established protocol (Ittner et al., 2010). Different from what we
had done previously (Ittner et al., 2010), we used whole fore-
brains rather than pooled hippocampi. We sequentially extracted
synaptosomes (n = 4 per genotype) from wild-type, FynCA and
FynCA × tau (Tau+/−) mice and analyzed the PSD fraction
containing the PSD for levels of Fyn, PSD-95, the NMDA receptor
subunit 2b (NR2b), NR2b phosphorylated at Y1472, tau, and tau
phosphorylated at the AT8 epitope S202/T205 and at the 12E8
epitope S262(/S356), using actin and PSD95 for normalization
(Figures 6A,B).We also obtained total brain extracts, and asmen-
tioned above, found that levels of transgenic FynCA expression
were approximately six-fold higher than endogenous murine Fyn
(Figure 6A).
When we analyzed the PSD fraction we detected massively
increased levels of Fyn in FynCA compared with wild-type mice.
When FynCA mice co-expressed tau, Fyn levels in the PSD
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FIGURE 6 | Western blot of total brain extract and synaptosomal fractions.
We compared wild-typemice (1,2), FynCAmice (3,4), and FynCAmice crossed
onto a tau background (5,6). (A) Total extracts and synaptosomal PSD (SDS)
fractions (B)were analyzed with antibodies for GAPDH, actin, Fyn (short and
long exposure), Myc, PSD-95, NR2b, NR2b phosphorylated at Y1472, total tau,
human tau (HT7) detecting tau, and phospho-tau (AT8, 12E8).
fraction were not reduced, suggesting that either high levels of
Fyn override the inhibition by tau in targeting Fyn to the spine
(as observed for normal Fyn levels in tau74 mice) or non-
overlapping expression patterns, or both. We found high levels
of tau in the PSD fraction. Interestingly, whereas in total extracts
obtained from FynCA mice, tau was massively phosphorylated at
the AT8 epitope (tau phosphorylated at S202/ S205) (reflecting
the histological data), we failed to detect tau phosphorylated at
AT8 in the PSD fraction. This would suggest that if tau in the
FynCA mice were phosphorylated at the AT8 epitope, levels in
the spines would be very low. Interestingly, when FynCA mice
were crossed onto a tau background, in total brain extracts,
tau phosphorylation at the AT8 epitope was strongly reduced.
Note: tau itself is not phosphorylated at the AT8 epitope, which
is in line with previous observations showing that tau is not
highly phosphorylated (Klein et al., 2002; Ittner et al., 2010). In
agreement with these previous data, tau is not targeted to the
PSD (Figure 6B). We also assessed tau phosphorylation at the
12E8 epitope (tau phosphorylated at S262 and possibly S356) and
found that for the FynCAmice, 12E8 phosphorylation in the PSD
fraction was increased compared with the fraction obtained from
non-transgenic littermate controls. This increase was slight and
not found in mice co-expressing FynCA and tau.
We further assessed NR2b phosphorylation and found that
Y1472 phosphorylation was approximately four-fold increased in
total extracts and in the PSD fraction obtained from FynCA com-
pared with wild-type mice, and that levels were also increased
when tau was co-expressed with FynCA.
DISCUSSION
Using two cellular systems we firstly showed that the palmitoyla-
tion signal is critical for the subcellular localization of the kinase
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Fyn: Mutating the two critical amino-terminal cysteine residues
into serines abrogates localization of Fyn to the plasmamembrane
in HEK293 cells, and to dendritic spines in primary neuronal cul-
tures. By mutating Y531 of Fyn to phenylalanine, we generated
mice that express a constitutively active form of Fyn in neurons.
These mice are characterized by early lethality around the age
of weaning, a massively reduced weight and hyperactivity. We
are also presenting preliminary evidence that constitutively active
Fyn causes phosphorylation of endogenous murine tau at serine
and threonine residues, as shown for the AT8 phospho-epitope
of tau by both immunohistochemistry and Western blot analysis.
Interestingly, tau in the spine seemed either not to be phosphory-
lated at AT8 at all or at least levels must be very low as we failed to
detect AT8 phosphorylation in the “PSD blot” that was processed
together with the “total blot.”
Fyn is a kinase that has been proposed to act as a signal inte-
gration hub that is involved in a vast number of cellular programs
(Wang et al., 2013). In a pathological context such as AD, Fyn has
been shown to integrate signals that ultimately lead to neuronal
demise. Fyn mediates the downstream toxicity of Aβ by over-
activating cellular receptors such as the NMDA receptor either
directly or indirectly (Ittner et al., 2010). An additional role has
been presented for the prion protein, PrPc. It has been shown that
Aβ-induced dendritic spine loss requires both PrPc and Fyn, and
that in mice lacking PrPc, human familial AD transgene-induced
convulsive seizures do not occur (Um et al., 2012). More recently,
the metabotropic glutamate receptor 5 (mGluR5) was shown to
function as a co-receptor of PrPc (Um et al., 2013). Soluble Aβ
was found to bind to PrPc at dendritic spines where PrPc forms
a complex with Fyn, resulting in the activation of Fyn and sub-
sequent Y18 phosphorylation, as shown with antibody anti-pY18
(Larson et al., 2012). However, how tau and Fyn are targeted to
the dendritic spine is not understood. Two scenarios have been
discussed previously (Larson et al., 2012): (i) Either Fyn is not
bound to tau before entering the spine and activated Fyn then
causes the phosphorylation of tau at Y18 resulting in its accumu-
lation at the PSD. It is possible that at this stage phosphorylated
Fyn might be bound to phosphorylated Tau binding to the SH3
domain of PSD-95, where it is ideally located to modulate NMDA
receptor subunits such as NR2b at residue Y1472 (Ittner et al.,
2010). (We found that FynCA is localized to the spine where it
phosphorylates NR2b at Y1472.) (ii) The alternative scenario is
that in the dendrite, Fyn is already bound to tau, which then
translocates to the PSD to interact with PSD-95. There, another
tyrosine kinase, Pyk2 (Köhler et al., 2013), could potentially acti-
vate Fyn and cause phosphorylation of tau at Y18. We found that
increased levels of activated Fyn causes increased levels of phos-
phorylated Tau in the FynCA mice as shown for the AT8 epitope,
although no increased phosphorylation was found for the spines.
A time-resolved model for how Aβ via Fyn ultimately causes neu-
ronal demise has been presented by Jannic Boehm, integrating the
effects of Aβ on Fyn and STEP, a Fyn-phosphatase that eventually
inactivates Fyn (Boehm, 2013).
Co-expressing tau and FynCA did not result in reduced lev-
els of Fyn in the synaptosomal compartment. We had previously
shown that transgenic expression of tau, which accumulates
in the soma and is prevented from entering the dendrites, traps
(endogenous) Fyn in the cell body and prevents it from entering
the spines (Ittner et al., 2010). When FynCA is massively over-
expressed, levels of tau seem not to be sufficiently high to pre-
vent Fyn from entering the spines suggesting that manipulation
of tau levels for therapeutic intervention may not be beneficial
when Fyn is highly activated and/or its levels are increased, as
may be the case under disease conditions. On the other hand
it has been reported for AD brain by quantitative immunoblot-
ting that Fyn levels were increased in the insoluble fraction and
decreased in the soluble fraction. Soluble Fyn levels were directly
correlated with cognitive scores and inversely correlated with tau-
containing neurofibrillary tangle counts in the frontal cortex (Ho
et al., 2005).
In spines it has been shown that hyperphosphorylated tau
abnormally accumulates (Hoover et al., 2010). We have shown
previously that in the presence of elevated levels of (phosphory-
lated) human tau, Aβ toxicity is exaggerated, most likely because,
under these conditions, more Fyn enters the spine (Ittner et al.,
2010; Ittner and Götz, 2011). In the presence of oligomeric Aβ
tau not only changes its phosphorylation status but also alters its
subcellular localization (Zempel et al., 2010, 2013). A role for tau
phosphorylation specifically at the 12E8 epitope Ser262/Ser356
has been shown to be required for Aβ-mediated spine loss medi-
ated via the CaMK2-AMPK signaling pathway (Mairet-Coello
et al., 2013). We found in the present study that increased
Fyn activity and levels in the spine do not necessarily result in
increased phosphorylation, at least as shown for the AT8 epi-
tope. This is different for the 12E8 phospho-epitope of tau, which
reveals a slight increase in the FynCA PSD fraction compared to
both non-transgenic littermate controls and mice co-expressing
FynCA and tau. Further work needs to go into how Fyn reg-
ulates tau phosphorylation and what the requirements are for
dendritic and spine localization of distinct phospho-pools of tau.
Whether the results of our study would have been different if we
had analyzed hippocampal fractions remains to be determined.
Earlier studies have been looking into transgenic mice that
expressed FynB Y531F controlled by a CaMKII/SV40 expression
vector (Kojima et al., 1998). The mice presented with higher
seizure susceptibility. They also showed enhanced tyrosine phos-
phorylation of the NR2b subunit of the NMDA receptor. This
was demonstrated by immuno-precipitating the NR2b subunit
from the PSD fraction, running a blot, and probing it with a
phospho-tyrosine-specific antibody.We confirmed this finding by
probing the PSD fraction directly with an NR2b phospho-Y1472-
specific antibody. Further work by Kojima and colleagues showed
that an impairment of long-term potentiation in the absence of
Fyn could be rescued by reintroducing FynB under control of the
CamKII promoter (Kojima et al., 1997). When the constitutively
active form of Fyn, Y528F was expressed in the epidermis using
the keratin 14 promoter for expression (Li et al., 2007), 10% of
homozygous mice died before weaning. Otherwise the mice were
normal in size, and as they aged they developed spontaneous skin
tumors. Together with our findings this reveals an important role
for Fyn in peripheral organs and the brain.
Further work is required to determine how Fyn and tau are
transported into the spine, which posttranslational modifica-
tions govern this process and which kinases are activated by the
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tyrosine kinase Fyn in order to cause serine/threonine-directed
phosphorylation of substrates such as tau.
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